What is the recommended dose of valaciclovir (Valtrex) for treating genital herpes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Valaciclovir Dosing for Genital Herpes

For first-episode genital herpes, use valaciclovir 1 gram twice daily for 7-10 days; for recurrent episodes, use 500 mg twice daily for 3-5 days; and for suppressive therapy, use 500 mg to 1 gram once daily depending on recurrence frequency. 1

First Episode (Initial Outbreak)

  • Valaciclovir 1 gram twice daily for 10 days is the recommended regimen for initial genital herpes episodes 1
  • Treatment is most effective when initiated within 48 hours of symptom onset 1
  • This dosing has been shown to be equally effective as aciclovir 200 mg five times daily in achieving lesion healing and reducing viral shedding 2, 3

Recurrent Episodes (Episodic Treatment)

  • Valaciclovir 500 mg twice daily for 3 days is the FDA-approved regimen for recurrent genital herpes 1
  • The CDC also supports 500 mg twice daily for 5 days as an alternative 4, 5
  • Initiate treatment at the first sign or symptom of recurrence (tingling, itching, burning) for maximum effectiveness 6, 1
  • Both the 3-day and 5-day regimens are equally effective as aciclovir 200 mg five times daily 2, 7

Suppressive Therapy (Daily Prevention)

Standard Dosing for Immunocompetent Patients

  • Valaciclovir 1 gram once daily is the standard suppressive dose for patients with normal immune function 1
  • For patients with 9 or fewer recurrences per year, 500 mg once daily is an acceptable alternative 1
  • Important caveat: 500 mg once daily is less effective in patients with ≥10 recurrences per year, who should receive 1 gram once daily 4, 5, 8

HIV-Infected Patients

  • For HIV-infected patients with CD4+ count >100 cells/mm³, use valaciclovir 500 mg twice daily for suppressive therapy 5, 1
  • This higher dosing accounts for potentially more severe and frequent recurrences in immunocompromised individuals 5

Clinical Efficacy and Duration

  • Daily suppressive therapy reduces recurrences by ≥75% among patients with frequent episodes 5
  • Safety and efficacy have been documented for up to 1 year with valaciclovir 5
  • After 1 year of continuous suppressive therapy, consider discussing discontinuation to reassess recurrence frequency, as recurrences often decrease over time 5

Important Safety Considerations

  • Avoid high-dose valaciclovir (8 grams per day) in immunocompromised patients due to risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome 5, 9
  • Standard doses (≤2 grams daily) used for genital herpes have not been associated with this complication 5
  • No laboratory monitoring is needed for patients on suppressive therapy unless substantial renal impairment exists 5
  • For patients with CrCl 30-49 mL/min, no dose reduction is needed; however, adjust doses for more severe renal impairment 5, 1

Treatment Failure

  • If lesions persist after 7-10 days of appropriate valaciclovir therapy, consider HSV resistance 5, 6
  • All aciclovir-resistant strains are also resistant to valaciclovir 5
  • For aciclovir-resistant HSV, IV foscarnet is the treatment of choice 5

Transmission Reduction

  • For reduction of transmission to uninfected partners in patients with ≤9 recurrences per year, valaciclovir 500 mg once daily is recommended 1
  • Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 4, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.